SCM
REGN icon

Sarissa Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Sarissa Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Hold
4,190
– – 1.47% 8
2026
Q1 		$3.24M Hold
4,190
– – 2.05% 8
2025
Q4 		$3.23M Hold
4,190
– – 1.45% 8
2025
Q3 		$2.36M Buy
+4,190
New +$2.37M 1.31% 7

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sarissa Capital Management's REGN Position: Q2 2026 in Review

Sarissa Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 4,190 shares worth $2.61M. The position accounts for 1.47% of the portfolio, ranked #8.

Sarissa Capital Management first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.24M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Sarissa Capital Management held 4,190 shares of Regeneron Pharmaceuticals worth $2.61M as of Q2 2026.
  • Sarissa Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 1.47% of Sarissa Capital Management's portfolio in Q2 2026, its #8 holding.
  • Sarissa Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Sarissa Capital Management's Regeneron Pharmaceuticals position peaked at $3.24M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sarissa Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.